Alopecia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of alopecia areata (AA) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of AA for each country, as well as annualized case counts projected to the national population. Patient populations are forecast over a period of 20 years.
Clarivate Epidemiology’s AA forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people who develop AA per year?
- Of all people diagnosed with AA, how many in each country across the world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of alopecia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 15 AA patient populations, as follows:
- Diagnosed incidence.
- Diagnosed 12-month prevalence.
- Diagnosed 12-month prevalence with depression.
- Diagnosed 12-month prevalence with anxiety.
- Diagnosed 12-month prevalence with thyroid disease.
- Diagnosed 12-month prevalence with asthma.
- Diagnosed 12-month prevalence with allergic rhinitis.
- Diagnosed 12-month prevalence with atopic dermatitis.
- Diagnosed 12-month prevalence with rheumatoid arthritis.
- Diagnosed 12-month prevalence with psoriasis.
- Diagnosed 12-month prevalence with vitiligo.
- Diagnosed 12-month prevalent cases with
- Diagnosed 12-month prevalent cases with 51-99% hair loss.
- Diagnosed alopecia totalis 12-month prevalent cases.
- Diagnosed alopecia universalis 12-month prevalent cases.
Note: coverage may vary by country.
